MP61-12WHICH MEN WITH CN1 PROSTATE CANCER AT PSMA PET/CT REPRESENT THE IDEAL CANDIDATE TO RADICAL PROSTATECTOMY? DEVELOPMENT OF A NOVEL RISK STRATIFICATION TOOL FOR INDIVIDUALIZED APPROACHES BASED ON A LARGE, MULTI-INSTITUTIONAL SERIESdoi:10.1097/JU.0000000000003319.12...
此前该团队开发了低分子量的PSMA靶向核药[211At]L3-Lu,本研究进一步评估了探针[211At]YF2,以确定更适合临床转化的分子。 方法:合成了[211At]YF2和[211At]L3-Lu各自的前体和未标记的碘标准品,并开发了一种新的一步标记法,从各自的锡前体制备[211At]YF2和[211At]L3-Lu。采用 RP-HPLC 法测定了RCY和RCP。
There was incidental detection of a PSMA-avid subcutaneous abdominal wall mass on PSMA PET/CT study, which was consistent with desmoid fibromatosis on an ultrasound-guided biopsy.关键词: F-18-piflufolastat PET/CT Pylarify desmoid tumor prostate carcinoma ...
Piflufolastat F 18对PSMA活性部位的特异性有助于防止可能导致不良后果的脱靶效应,而18F放射性核素的信号输出强,可使用相对小剂量的Piflufolastat F 18,这种安全性与其他小分子PSMA-PET药物类似[17]。 在OSPREY和CONDOR 2项试验中合并的593例患者中评估Piflufolastat F 18的安全性,每位患者都接受1次剂量的Pi...
多参数磁共振成像(mp-MRI)可帮助检测临床意义显著上的前列腺癌.PSMA靶向PET成像已经显示出作为非侵入性测试的前景,有助于检测临床意义显著的前列腺癌,同时提供解剖学信息以指导靶向活组织检查.PSMA靶向PET与mpMRI联合使用可提供更高程度的诊断准确性.笔者就前列腺特异性膜抗原(PSMA)靶向PET成像在临床意义显著前列腺癌诊...
近期,FDA已经批准了Pylarify(piflufolastatF 18),一种用于前列腺癌患者前列腺特异性膜抗原(PSMA)阳性病变的正电子发射断层显像(PET)药物。 随着Pylarify的批准,某些患有前列腺癌的男性将有更多的机会获得PSMA靶向PET成像,这可以帮助医疗提供者评估前列腺癌。
The FDA has approved piflufolastat F 18 (Pylarify) injection, a prostate-specific membrane antigen (PSMA)–targeted positron emission tomography (PET) imaging agent, to identify suspected metastasis or recurrence of prostate cancer. The product will be made immediately available to parts ...
“SiC and GaN have been the most popular topics at APEC over the past several years. It is clear that the promise that these devices have offered in size and efficiency gains are being realized,” comments PSMA Semiconductor Committee chairman Tim McDonald. “This ‘Coming of Age’ series of...
#前列腺##adc药物# 【Ambrx旗下PSMA ADC获FDA授予快速通道资格】$Ambrx Biopharma AMAM$ 7月19日,Ambrx宣布ARX517获FDA授予快速通道资格,用于治疗接受雄激素受体通路抑制剂治疗后疾病进展的转移性去势抗性前列腺癌(mCRPC)。ARX517是Ambrx利用其遗传密码扩增(expanded genetic code)技术开发的一款潜在同类首创ADC,由全人...
However, the optimal onset of ADT at PSA relapse is unknown, especially in patients with normal testosterone. In our case a limited PSMA avid lymph node was detected on PET/CT. Our case highlights the importance of metastasis-directed therapy balancing general versus tailored treatment in the ...